Awards & Achievements

CSI Principal Associate, Dr. Alan Prem Kumar, Receives Korean Breast Cancer Foundation Scholarship

CSI Singapore is delighted to congratulate our Principal Associate, Dr Alan Prem Kumar for receiving the Korean Breast Cancer Foundation Scholarship for his outstanding oral presentation and active participation in the Global Breast Cancer Conference 2016. This conference was held on 28 -30 April 2016 in Jeju Island, Korea.

The Global Breast Cancer Conference is a meeting of breast cancer held in Korea hosted by the Korean Breast Cancer Society and supported by the Korea Breast Cancer Foundation. It takes place annually to promote the exchange of inspiring ideas and current issues in the field of breast cancer.

During this conference, Dr Kumar shared about his research on DEAD-box helicase, DP103 and its effectiveness as a biomarker for drug response in ERα positive breast cancer patients.

GBCC Award - Alan


DEAD-box RNA Helicase DP103 as a Biomarker for Therapeutic Response to Docetaxel

Abstract:

Resistance to chemotherapy offers limitations to the treatment of breast cancer. This has generated an increased interest in identifying new biomarkers to better predict drug responses among patients. Gene expression analysis and immuno-histochemistry profiling of patient samples, randomized to a combination of docetaxel and doxorubicin, revealed a chemotherapy induced decrease in DP103 expression among responders, and an increase among non-responders. These clinical findings were also validated in-vitro, using representative cell lines to mimic responders, and their corresponding drug resistant subtypes as non-responders. Upon stratification by the receptor status, the predictive value of DP103 was only observed in patient samples and cell lines with ERα-positive status and not with ERα-negative status. The observed changes in DP103 expression was well correlated to a similar drug induced change in the expression of ERα; raising a possibility of a cross-talk between DP103 and ERα. ChIP-Seq analysis and estradiol-stimulation studies validated DP103 to be an estrogen-inducible gene. Interestingly, DP103 was also indentified as a potential modulator of ERα transcriptional activity. Silencing DP103 inhibited estradiol-induced ERα DNA-binding activity, expression of ERα target genes, cell growth and colony forming ability. These findings summarise a novel role of DP103 in acquired drug resistance; presenting a potential surrogate biomarker for predicting drug response in breast cancer. In addition, we have also uncovered a positive feed-forward loop between DP103 and ERα that could regulate the activity of the latter in ERα positive breast cancer.